Every material Form 8-K KALA BIO, Inc. has filed with the SEC since August 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
KALA BIO reported preliminary, unaudited results for the quarter ended September 30, 2026, showing a net loss of approximately $0.8 million, down from $7.6 million a year earlier. Cash, cash equivalents and short-term investments were approximately $7.0 million with no debt, and the company expects to file its Form 10-Q on or about November 16, 2026. Final results may differ from these preliminary figures, which shareholders should weigh against the pending review.
Q3 2026 net loss of approximately $0.8 million vs. $7.6 million in Q3 2025
Nine-month 2026 net loss of approximately $4.0 million vs. $27.7 million in the same period of 2025
Cash, cash equivalents and short-term investments of approximately $7.0 million as of September 30, 2026, with no debt
Form 10-Q expected on or about November 16, 2026; results remain preliminary and unaudited
KALA BIO entered into an Exclusive Distribution and Reseller Agreement with Virotek, Inc. on September 3, 2026, appointing Kala as sole distributor and reseller in the United States of a genetic testing and screening program for ophthalmology. Net profit from the program is split equally after Virotek recovers cost of goods sold, and the filing does not disclose any upfront payment or financial projections for the deal.
Agreement dated September 3, 2026 with Virotek, a Wyoming corporation; initial term of five years
Exclusivity converts to non-exclusive if Kala misses a milestone in Exhibit B by September 3, 2027, after a 30-day cure period
Net profit split equally between Virotek and Kala after cost of goods sold is recovered by Virotek
Virotek granted Kala a right of first refusal on certain dispositions of ophthalmological products, with at least 30 days to exercise
KALA BIO's board set November 3, 2026 as the date of its next annual stockholders meeting. Stockholders who want to submit proposals for inclusion in the proxy materials, or nominate directors, must do so by September 19, 2026, because the meeting date moved by more than 30 days from the prior anniversary.
Annual meeting date set for November 3, 2026; the board set the date on September 9, 2026
Deadline for Rule 14a-8 stockholder proposals for proxy inclusion: September 19, 2026
Deadline for director nominations and other proposals under the By-Laws: September 19, 2026, at the company's Arlington, Massachusetts offices
Meeting time, location and voting matters will be detailed in the proxy statement
KALA BIO received a Nasdaq Staff Determination Letter on August 27, 2026, stating its common stock closed below $1.00 for 30 consecutive business days and it is out of compliance with the minimum bid price rule. Because the company effected a 1-for-50 reverse stock split on May 11, 2026, it is not eligible for a standard 180-day compliance period, and the company plans to request a Nasdaq Hearings Panel review, which would stay any delisting action while pending.
Nasdaq Staff determined the stock closed below $1.00 from July 16, 2026 through August 26, 2026, 30 consecutive business days.
No 180-day compliance period is available because the company effected a 1-for-50 reverse stock split on May 11, 2026.
KALA BIO intends to timely request a hearing before the Nasdaq Hearings Panel; a timely request stays suspension or delisting pending the Panel's decision.
The company states there is no assurance the Panel will grant continued listing or that it will regain compliance.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every KALA BIO, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →